甲状腺癌患者血清中SIL-2R测定的临床意义

测定 59例甲状腺良、恶性疾病患者血清中可溶性白介素 受体 (SIL- 2 R)。结果显示 :甲状腺癌患者血清中 SIL- 2 R明显高于良性疾病组及对照组 (P <0 .0 1 )。良性腺瘤及结节性甲状腺肿与对照组间无明显差异 (P >0 .0 5)。甲状腺癌术后 5～ 1 0 d血清中 SIL- 2 R较术前增高 ,可能与术前血清中 SIL- 2 R高水平及手术干扰机体免疫有关。术后约 2 0 d基本降至正常。甲状腺癌血清中 SIL- 2 R升高与甲状腺癌的病理类型无明显关系。提示检测血清中 SIL- 2 R对判别甲状腺疾病良、恶性 ,估计疗效及预后有一定临床意义

The clinical significance of measuring serum SIL-2R in patients with thyroid carcinoma

The study measured serum SIL 2R level in 59 patients with thyroid benign of malignant disease.Results showed that serum SIL 2R level in patients with thyroid carcinoma was obviously higher than benign disease group and control group(P<0.01).There was no significant difference between benign adenoma and nodular goiter and control group(P<0 05).Serum SIL 2R level in 5 to 10 d after operation was higher than before in patients with thyroid carcinoma.It is probably associated with high serum SIL 2R level before SIL 2R level decreased essentially to normal in 20 d after operation .Serum high SIL 2R level is not correlated with the pathologic type in thyroid carcinoma.These suggest that there is clinical significance for distinguishing thyroid benign disease from malignant, evaluating curative effect and prognosis by measuring serum SIL 2R level.